Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease

Journal of Hypertension

Volumn 27, Issue 3, 2009, Pages 633-641

  Nardi, Emilio ^a,b   Palermo, Alessandro ^a   Mulè, Giuseppe ^a   Cusimano, Paola ^a   Cottone, Santina ^a   Cerasola, Giovanni ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b NONE   (Italy)

Author keywords

Chronic kidney disease; Heart diseases; Hypertension; Inappropriate left ventricular mass; Left ventricular hypertrophy

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; ESSENTIAL HYPERTENSION; FEMALE; GEOMETRY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IMAGE ANALYSIS; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MUSCLE MASS; PREVALENCE; PRIORITY JOURNAL; THICKNESS;

EID: 67649540424     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283220ecd     Document Type: Article

References (50)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (Suppl 3): S112-S119.
2. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA, The Hypertension Detection and Follow-up Program Cooperative Group. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the Hypertension Detection and Follow-up Program. Hypertension 1989; 13 (Suppl 5):S180-S193.
3. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41:47-55.
4. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63:1121-1129.
5. Guyton AC, Coleman TG, Wilcox CS. Quantitative analysis of the pathophysiology of hypertension. J Am Soc Nephrol 1999; 10:2248-2249.
6. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912-1918.
7. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004; 65:1568-1576.
8. Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116:85-97.
9. Locatelli F, Bommer J, London GM, Martín-Malo A, Wanner C, Yaqoob M, Zoccali C. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrol Dial Transplant 2001; 16:459-468.
10. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998; 9:1018-1022.
11. Amann K, Miltenberger-Miltenyi G, Simonoviciene A, Koch A, Orth S, Ritz E. Remodeling of resistance arteries in renal failure: effect of endothelin receptor blockade. J Am Soc Nephrol 2001; 12:2040-2050.
12. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end stage renal disease therapy. Kidney Int 1995; 47:186-192.
13. Levin A, Thompson C, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, et al. Left ventricular mass index increase in early renal disease: impact in decline in haemoglobin. Am J Kidney Dis 1999; 34:125-134.
14. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barré PE. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995; 5:2024-2031.
15. Stack AG, Saran R. Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. Am J Kidney Dis 2002; 40:1202-1210.
16. Muiesan ML, Salvetti M, Paini A, Monteduro C, Galbassini G, Bonzi B, et al. Inappropriate left ventricular mass changes during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2007; 49:1077-1083.
17. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183-1197.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
20. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(Suppl 1):S1-S266.
21. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58:1072-1073.
22. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
23. De Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and the impact of overweight. J Am Coll Cardiol 1992; 20:1251-1260.
24. Skiller N, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2:358-367.
25. De Simone G, Devereux RB, Kimball TR, Mureddu GF, Roman MJ, Contaldo F, Daniels SR. Interaction between body size and cardiac workload. Influence on left ventricular mass during body growth and adulthood. Hypertension 1998; 31:1077-1082.
26. Muiesan ML, de Simone G, Ganau A, Longhini C, Verdecchia P, Mancia G, Agabiti-Rosei E, Working Group on Heart and Hypertension of Italian Society of Hypertension. Inappropriate LV mass: reliability and limitations of echocardiographic measurement for risk stratification and follow-up in single patients: the RES study. J Hypertens 2006; 24:2293-2299.
27. Shan K, Bick RJ, Poindexter BJ, Shimoni S, Letsou GV, Reardon MJ, et al. Relation of tissue Doppler derived myocardial velocities to myocardial structure and beta-adrenergic receptor density in humans. J Am Coll Cardiol 2000; 36:891-896.
28. Gottdiener JS, Reda DJ, Materson BJ, Massie BM, Notargiacomo A, Hamburger RJ, et al. Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. J Am Coll Cardiol 1994; 24:1492-1498.
29. Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 1994; 4:1486-1490.
30. London G. Pathophysiology of cardiovascular damage in the early renal population. Nephrol Dial Transplant 2001; 16 (Suppl 2):3-6.
31. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003; 41 (Suppl 5):S11-S17.
32. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001; 12:1079-1084.
33. Nardi E, Cottone S, Mulè G, Palermo A, Cusimano P,Cerasola G. Influence of chronic renal insufficiency on left ventricular diastolic function in hypertensives without left ventricular hypertrophy. J Nephrol 2007; 20:320-328.
34. Tucker B, Fabbian F, Giles M, Thuraisingham C, Raine AEG, Baker LRI. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant 1997; 12:724-728.
35. Henry RM, Kamp O, Kostense PJ, Spijkerman AM, Dekker JM, Nijpels G, et al. Mild renal insufficiency is associated with increased left ventricular mass in men, but not in women: an arterial stiffness-related phenomenon -the Hoorn study. Kidney Int 2005; 68:673-679.
36. Paoletti E, Bellino D, Casottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis 2005; 46:320-327.
37. London GM. Left ventricular alteration and end-stage renal disease. Nephrol Dial Transplant 2002; 17:29-36.
38. Fathi R, Isbel N, Haluska B, Case C, Johnson DW, Marwick TH. Correlates of subclinical left ventricular dysfunction in ESRD. Am J Kidney Dis 2003; 41:1016-1025.
39. Miyazato J, Horio T, Takiuchi S, Kamide K, Sasaki O, Nakamura S, et al. Left ventricular diastolic dysfunction in patients with chronic renal failure: impact of diabetes mellitus. Diabet Med 2005; 22:730-736.
40. Bruch C, Rothenburger M, Gotzmann M, Witcher T, Scheld HH, Breithardt G, et al. Chronic kidney disease in patients with chronic heart failure: impact on intracardiac conduction, diastolic function and prognosis. Int J Cardiol 2007; 118:375-380.
41. Ahmed A, Rich M, Sanders P,PerryJ, Bakris G, Zile M, et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol 2007; 99:393-398.
42. Quiñones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for Quantification of Doppler Echocardiography: a report from the Doppler Quantification Task Force ofthe Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002; 15:167-184.
43. Choong CY, Herrmann HC, Weyman AE, Fifer MA. Preload dependence of Doppler-derived indexes of left ventricular diastolic function in humans. J Am Coll Cardiol 1987; 10:800-808.
44. Sohn DW, Chai IH, Lee DJ, Kim HC, Kim HS, Oh BH, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997; 30:474-480.
45. Lopez B, Gonzalez A, Varo N, Laviades C, Querejeta R, Diez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001; 38:1222-1226.
46. Lopez B, Gonzalez A, Lsarte JJ, Sarobe P, Borrás F, D́iaz A, et al. Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens 2005; 23:625-632.
47. Smedrod B, Melkko J, Risteli L, Risteli J. Circulating C-terminal propeptide of type I procollagen is cleared mainly via a mannose receptor in the liver endothelial cells. Biochem J 1990; 271:345-350.
48. Cottone S, Nardi E, Mulè G, Vadalà A, Lorito MC, Riccobene R, et al. Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. Clin Nephrol 2007; 67:209-216.
49. Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedorova L, Khouri S, et al. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 2006; 47:488-495.
50. Stella P, Manunta P, Mallamaci F, Melandri M, Spotti D, Tripepi G, et al. Endogenous ouabain and cardiomyopathy in dialysis patients. J Intern Med 2008; 263:274-280.